New Zealand markets closed
  • NZX 50

    -115.54 (-1.06%)

    -0.0083 (-1.32%)

    -0.0052 (-0.88%)

    -26.10 (-0.39%)
  • ASX 200

    -28.20 (-0.43%)
  • OIL

    +2.66 (+2.52%)
  • GOLD

    -20.40 (-1.13%)

    -154.55 (-1.33%)
  • FTSE

    -18.24 (-0.25%)
  • Dow Jones

    -253.88 (-0.82%)
  • DAX

    -17.32 (-0.14%)
  • Hang Seng

    -137.10 (-0.62%)
  • NIKKEI 225

    -457.42 (-1.73%)

    -1.3840 (-1.63%)

Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development Pipeline Guide 2022 -

·4-min read

DUBLIN, May 18, 2022--(BUSINESS WIRE)--The "Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to's offering.

The Pharmaceutical and Healthcare disease pipeline guide provides an overview of the Juvenile Macular Degeneration pipeline landscape.

The guide provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Juvenile Macular Degeneration pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 7, 1, 14 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration.

  • The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Juvenile Macular Degeneration therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Juvenile Macular Degeneration therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration

Key Topics Covered:

Juvenile Macular Degeneration (Stargardt Disease) - Overview

Therapeutics Development

  • Pipeline Overview

  • Pipeline by Companies

  • Pipeline by Universities/Institutes

  • Products under Development by Companies

  • Products under Development by Universities/Institutes

Therapeutics Assessment

  • Assessment by Target

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

Companies Involved in Therapeutics Development

  • 4P-Pharma SAS

  • Alkeus Pharmaceuticals Inc

  • Alnylam Pharmaceuticals Inc

  • Alpine Biotherapeutics Corp

  • Applied Genetic Technologies Corp

  • Astellas Pharma Inc

  • Beam Therapeutics Inc

  • Belite Bio Inc

  • Biophytis SA

  • Brooklyn ImmunoTherapeutics Inc

  • Cardax Inc

  • Coave Therapeutics

  • Copernicus Therapeutics Inc

  • Curative Biotechnology Inc

  • Fera Pharmaceuticals LLC

  • Generation Bio Co

  • Grupo Ferrer Internacional SA

  • IVERIC bio Inc

  • jCyte Inc

  • Katairo GmbH

  • Kubota Vision Inc

  • Lysoclear Inc

  • Mediphage Bioceuticals Inc

  • Nanoscope Therapeutics Inc

  • Oak bay Biosciences Ltd

  • ProQR Therapeutics NV

  • Ray Therapeutics Inc

  • ReVision Therapeutics Inc

  • Saliogen Therapeutics Inc

  • Shape Therapeutics Inc

  • Spark Therapeutics Inc

  • Splice Bio SL

  • Stargazer Pharmaceuticals Inc

Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles

  • 4P-020 - Drug Profile

  • ALK-001 - Drug Profile

  • ASP-7317 - Drug Profile

  • avacincaptad pegol sodium - Drug Profile

  • BIO-201 - Drug Profile

  • CDX-301 - Drug Profile

  • CTxABCA-4 - Drug Profile

  • emixustat hydrochloride - Drug Profile

  • FAB-111 - Drug Profile

  • Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile

  • Gene therapy for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile

  • Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile

  • GTSG - Drug Profile

  • Jcell - Drug Profile

  • metformin - Drug Profile

  • miniABCA4: STGD1 - Drug Profile

  • QR-1011 - Drug Profile

  • RAY-001 - Drug Profile

  • REV-0100 - Drug Profile

  • SHP-261 - Drug Profile

  • soraprazan - Drug Profile

  • STG-001 - Drug Profile

  • TFB for Dry Age-Related Macular Degeneration, Stargardt Macular Dystrophy - Drug Profile

  • tinlarebant - Drug Profile

  • VMCO-1 - Drug Profile

  • vutrisiran - Drug Profile

Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects

Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones

Featured News & Press Releases

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting